Finding a cure for tuberous sclerosis complex: from genetics through to targeted drug therapies

McEneaney, Lauren J. and Tee, Andrew R. ORCID: https://orcid.org/0000-0002-5577-4631 2019. Finding a cure for tuberous sclerosis complex: from genetics through to targeted drug therapies. Advances in Genetics 103 , pp. 91-118. 10.1016/bs.adgen.2018.11.003

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (627kB) | Preview

Abstract

Tuberous sclerosis complex (TSC) is a rare, autosomal dominant genetic condition caused by a mutation in either the TSC1 or TSC2 gene. Phenotypically, this leads to aberrant cell growth and the formation of benign tumors called hamartomas in multiple organs. Understanding the mechanisms of pathology that are caused through the presence of disease causing mutations is a real hurdle for many rare genetic disorders; a limiting factor that restricts knowledge of the disease and any hope of a future cure. Through the discovery of the TSC1 and TSC2 genes and the signaling pathways responsible for the pathology of TSC, a new drug target called mechanistic target of rapamycin complex 1 (mTORC1) was discovered. Rapamycin, an mTORC1 inhibitor, is now the only pharmacological therapy approved for the treatment of TSC. This chapter summarizes the success story of TSC and explores the future possibilities of finding a cure.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	0065-2660
Date of First Compliant Deposit:	21 January 2019
Date of Acceptance:	21 January 2019
Last Modified:	21 Nov 2024 21:15
URI:	https://orca.cardiff.ac.uk/id/eprint/118552

Citation Data

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item